The activation of the aryl hydrocarbon receptor (AhR) by xenobiotic compounds was demonstrated to result in the degradation of the androgen receptor (AR). Since prostate cancer is often dependent on AR, it has become a significant therapeutic target. As a result of the emerging concept of bacterial mimicry, we tested whether compounds with indole scaffolds capable of AhR activation have the potential to restrict AR activity in prostate cancer cells. Altogether, 22 indolic compounds were tested, and all of them activated AhR. However, only eight decreased DHT-induced AR luciferase activity. All indoles, which met the AhR-activating and AR-suppressing criteria, decreased the expression of DHT-inducible AR target genes, specifically KLK3 and FKBP5 mRNAs. The reduced AR binding to the KLK3 promoter was confirmed by a chromatin immunoprecipitation (ChIP) assay. In addition, some indoles significantly decreased AR protein and mRNA level. By using CRISPR/Cas9 AhR knockout technology, no relationship between AhR and AR, measured as target gene expression, was observed. In conclusion, some indoles that activate AhR possess AR-inhibiting activity, which seems to be related to the downregulation of AR expression rather than to AR degradation alone. Moreover, there does not seem to be a clear relationship that would connect AhR activation with AR activity suppression in 22Rv1 cells.

Department of Cell Biology and Genetics Faculty of Science Palacky University Olomouc Slechtitelu 27 783 71 Olomouc Czech Republic

Zobrazit více v PubMed

Dunn M.W., Kazer M.W. Prostate cancer overview. Semin. Oncol. Nurs. 2011;27:241–250. doi: 10.1016/j.soncn.2011.07.002. PubMed DOI

Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. PubMed DOI

Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166. PubMed DOI

Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., Nelson P.S. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Cancer Res. 2008;68:4447–4454. doi: 10.1158/0008-5472.CAN-08-0249. PubMed DOI PMC

Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22. doi: 10.1158/0008-5472.CAN-08-2764. PubMed DOI PMC

Zhang T., Karsh L.I., Nissenblatt M.J., Canfield S.E. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clin. Genitourin. Cancer. 2020;18:1–10. doi: 10.1016/j.clgc.2019.09.015. PubMed DOI

Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., Chen Y., Mohammad T.A., Chen Y., Fedor H.L., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014;371:1028–1038. doi: 10.1056/NEJMoa1315815. PubMed DOI PMC

Kenji A. Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Applications. 1st ed. Springer; Boston, MA, USA: 2002.

Bruchovsky N., Wilson J.D. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 1968;243:2012–2021. doi: 10.1016/S0021-9258(18)93542-8. PubMed DOI

Sharifi N., Auchus R.J. Steroid biosynthesis and prostate cancer. Steroids. 2012;77:719–726. doi: 10.1016/j.steroids.2012.03.015. PubMed DOI

Ghotbaddini M., Moultrie V., Powell J.B. Constitutive Aryl Hydrocarbon Receptor Signaling in Prostate Cancer Progression. J. Cancer Treat. Diagn. 2018;2:11–16. doi: 10.29245/2578-2967/2018/5.1136. PubMed DOI PMC

Schellhammer P.F., Sharifi R., Block N.L., Soloway M.S., Venner P.M., Patterson A.L., Sarosdy M.F., Vogelzang N.J., Chen Y., Kolvenbag G.J. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996;78:2164–2169. doi: 10.1002/(SICI)1097-0142(19961115)78:10<2164::AID-CNCR18>3.0.CO;2-X. PubMed DOI

Poellinger L. Mechanistic aspects--the dioxin (aryl hydrocarbon) receptor. Food Addit. Contam. 2000;17:261–266. doi: 10.1080/026520300283333. PubMed DOI

Mimura J., Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta. 2003;1619:263–268. doi: 10.1016/S0304-4165(02)00485-3. PubMed DOI

Ohtake F., Baba A., Fujii-Kuriyama Y., Kato S. Intrinsic AhR function underlies cross-talk of dioxins with sex hormone signalings. Biochem. Biophys. Res. Commun. 2008;370:541–546. doi: 10.1016/j.bbrc.2008.03.054. PubMed DOI

De Anna J.S., Darraz L.A., Painefilu J.C., Carcamo J.G., Moura-Alves P., Venturino A., Luquet C.M. The insecticide chlorpyrifos modifies the expression of genes involved in the PXR and AhR pathways in the rainbow trout, Oncorhynchus mykiss. Pestic. Biochem. Physiol. 2021;178:104920. doi: 10.1016/j.pestbp.2021.104920. PubMed DOI

Kizu R., Okamura K., Toriba A., Kakishima H., Mizokami A., Burnstein K.L., Hayakawa K. A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells. Arch. Toxicol. 2003;77:335–343. doi: 10.1007/s00204-003-0454-y. PubMed DOI

Fritz W.A., Lin T.M., Cardiff R.D., Peterson R.E. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis. 2007;28:497–505. doi: 10.1093/carcin/bgl179. PubMed DOI

Ohtake F., Baba A., Takada I., Okada M., Iwasaki K., Miki H., Takahashi S., Kouzmenko A., Nohara K., Chiba T., et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature. 2007;446:562–566. doi: 10.1038/nature05683. PubMed DOI

Ghotbaddini M., Powell J.B. The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells. Int. J. Environ. Res. Public Health. 2015;12:7506–7518. doi: 10.3390/ijerph120707506. PubMed DOI PMC

Sanada N., Gotoh Y., Shimazawa R., Klinge C.M., Kizu R. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5alpha-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D cells. J. Pharmacol. Sci. 2009;109:380–387. doi: 10.1254/jphs.08328FP. PubMed DOI

Arabnezhad M.R., Montazeri-Najafabady N., Chatrabnous N., Ghafarian Bahreman A., Mohammadi-Bardbori A. Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020;153:108508. doi: 10.1016/j.steroids.2019.108508. PubMed DOI

Morrow D., Qin C., Smith R., 3rd, Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol. 2004;88:27–36. doi: 10.1016/j.jsbmb.2003.10.005. PubMed DOI

Sun F., Indran I.R., Zhang Z.W., Tan M.H., Li Y., Lim Z.L., Hua R., Yang C., Soon F.F., Li J., et al. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. Carcinogenesis. 2015;36:757–768. doi: 10.1093/carcin/bgv040. PubMed DOI PMC

Chen Z., Cai A., Zheng H., Huang H., Sun R., Cui X., Ye W., Yao Q., Chen R., Kou L. Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor. Oncogenesis. 2020;9:49. doi: 10.1038/s41389-020-0236-x. PubMed DOI PMC

He C., Wang Z., Shi J. Chapter Seven—Pharmacological effects of icariin. In: Du G., editor. Advances in Pharmacology. Volume 87. Academic Press; Cambridge, MA, USA: 2020. pp. 179–203. PubMed

Szabo R., Racz C.P., Dulf F.V. Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review. Int. J. Mol. Sci. 2022;23:7519. doi: 10.3390/ijms23147519. PubMed DOI PMC

Seeberger L.C., Hauser R.A. Levodopa/carbidopa/entacapone in Parkinson’s disease. Expert Rev. Neurother. 2009;9:929–940. doi: 10.1586/ern.09.64. PubMed DOI

Stepankova M., Bartonkova I., Jiskrova E., Vrzal R., Mani S., Kortagere S., Dvorak Z. Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol. Pharmacol. 2018;93:631–644. doi: 10.1124/mol.118.112151. PubMed DOI PMC

Bartonkova I., Novotna A., Dvorak Z. Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity. PLoS One. 2015;10:e0121316. doi: 10.1371/journal.pone.0121316. PubMed DOI PMC

Lee C.H., Ku J.Y., Ha J.M., Bae S.S., Lee J.Z., Kim C.S., Ha H.K. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. Prostate. 2017;77:60–71. doi: 10.1002/pros.23248. PubMed DOI

ATCC The Global Bioresource Center—LNCaP. [(accessed on 20 June 2022)]. Available online: https://www.atcc.org/products/crl-1740.

Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int. J. Cancer. 1994;57:406–412. doi: 10.1002/ijc.2910570319. PubMed DOI

Tran C., Richmond O., Aaron L., Powell J.B. Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells. Biochem. Pharmacol. 2013;85:753–762. doi: 10.1016/j.bcp.2012.12.010. PubMed DOI PMC

Suyama Y., Hirayama C. Serum indole and skatole in patients with various liver diseases. Clin. Chim. Acta. 1988;176:203–206. doi: 10.1016/0009-8981(88)90208-2. PubMed DOI

Larigot L., Juricek L., Dairou J., Coumoul X. AhR signaling pathways and regulatory functions. Biochim. Open. 2018;7:1–9. doi: 10.1016/j.biopen.2018.05.001. PubMed DOI PMC

Nichols W.K., Mehta R., Skordos K., Macé K., Pfeifer A.M., Carr B.A., Minko T., Burchiel S.W., Yost G.S. 3-methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicol. Sci. 2003;71:229–236. doi: 10.1093/toxsci/71.2.229. PubMed DOI

Novotna A., Pavek P., Dvorak Z. Novel stably transfected gene reporter human hepatoma cell line for assessment of aryl hydrocarbon receptor transcriptional activity: Construction and characterization. Environ Sci. Technol. 2011;45:10133–10139. doi: 10.1021/es2029334. PubMed DOI